APA (7th ed.) Citation

M, T., T, Y., K, S., N, G., T, U., H, I., . . . Y, O. (2024). Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report. JTO clinical and research reports, 5(4), 100657. https://doi.org/10.1016/j.jtocrr.2024.100657

Chicago Style (17th ed.) Citation

M, Torasawa, et al. "Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report." JTO Clinical and Research Reports 5, no. 4 (2024): 100657. https://doi.org/10.1016/j.jtocrr.2024.100657.

MLA (9th ed.) Citation

M, Torasawa, et al. "Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report." JTO Clinical and Research Reports, vol. 5, no. 4, 2024, p. 100657, https://doi.org/10.1016/j.jtocrr.2024.100657.